(CBT) Cabot - Ratings and Ratios
Carbon Black,Fumed Silica,Fumed Alumina,Aerogel Gel,Conductive Compound
CBT EPS (Earnings per Share)
CBT Revenue
Description: CBT Cabot
Cabot Corporation is a specialty chemicals and performance materials company operating through two segments: Reinforcement Materials and Performance Chemicals. The company provides a range of products, including reinforcing carbons, specialty carbons, conductive additives, fumed silica, and aerogel, used in various applications such as tires, industrial products, inks, coatings, and electronics.
The companys product portfolio is diverse, catering to multiple industries, including automotive, industrial, packaging, infrastructure, agriculture, consumer products, and electronics. Cabot Corporations products are sold through distributors and sales representatives across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, indicating a strong global presence.
From a financial perspective, Cabot Corporation has a market capitalization of approximately $4.07 billion, with a price-to-earnings ratio of 9.82, indicating a relatively undervalued stock. The companys return on equity (ROE) is 31.13%, suggesting a strong ability to generate profits from shareholder equity. To further evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating cash flow margin can be analyzed. For instance, a high gross margin could indicate a competitive advantage, while a strong operating cash flow margin could suggest efficient operations.
Additionally, Cabot Corporations dividend yield and payout ratio can be examined to assess its attractiveness to income-seeking investors. A stable or increasing dividend payout can indicate a companys commitment to returning value to shareholders. Furthermore, the companys debt-to-equity ratio and interest coverage ratio can be analyzed to evaluate its financial leverage and ability to meet interest payments.
CBT Stock Overview
| Market Cap in USD | 4,158m |
| Sub-Industry | Commodity Chemicals |
| IPO / Inception | 1980-11-05 |
CBT Stock Ratings
| Growth Rating | 17.8% |
| Fundamental | 73.3% |
| Dividend Rating | 66.2% |
| Return 12m vs S&P 500 | -31.8% |
| Analyst Rating | 3.60 of 5 |
CBT Dividends
| Dividend Yield 12m | 2.64% |
| Yield on Cost 5y | 6.30% |
| Annual Growth 5y | 3.84% |
| Payout Consistency | 94.0% |
| Payout Ratio | 23.9% |
CBT Growth Ratios
| Growth Correlation 3m | 53.1% |
| Growth Correlation 12m | -88.5% |
| Growth Correlation 5y | 90.4% |
| CAGR 5y | 18.72% |
| CAGR/Max DD 5y | 0.50 |
| Sharpe Ratio 12m | -2.01 |
| Alpha | -35.09 |
| Beta | 0.887 |
| Volatility | 36.30% |
| Current Volume | 211k |
| Average Volume 20d | 366.3k |
| Stop Loss | 78.8 (-3.4%) |
| Signal | -1.56 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (425.0m TTM) > 0 and > 6% of Revenue (6% = 228.9m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -2.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.83% (prev 22.08%; Δ -0.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 650.0m > Net Income 425.0m (YES >=105%, WARN >=100%) |
| Net Debt (976.0m) to EBITDA (812.0m) ratio: 1.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (53.8m) change vs 12m ago -3.41% (target <= -2.0% for YES) |
| Gross Margin 25.16% (prev 23.90%; Δ 1.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 102.9% (prev 110.6%; Δ -7.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.81 (EBITDA TTM 812.0m / Interest Expense TTM 75.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.94
| (A) 0.22 = (Total Current Assets 1.57b - Total Current Liabilities 740.0m) / Total Assets 3.84b |
| (B) 0.48 = Retained Earnings (Balance) 1.85b / Total Assets 3.84b |
| (C) 0.18 = EBIT TTM 661.0m / Avg Total Assets 3.71b |
| (D) 0.72 = Book Value of Equity 1.54b / Total Liabilities 2.15b |
| Total Rating: 4.94 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.34
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 6.78% = 3.39 |
| 3. FCF Margin 9.12% = 2.28 |
| 4. Debt/Equity 0.79 = 2.20 |
| 5. Debt/Ebitda 1.50 = 0.96 |
| 6. ROIC - WACC 12.25% = 12.50 |
| 7. RoE 29.52% = 2.46 |
| 8. Rev. Trend -61.10% = -3.05 |
| 9. Rev. CAGR -6.55% = -1.09 |
| 10. EPS Trend 29.14% = 0.73 |
| 11. EPS CAGR 4.69% = 0.47 |
What is the price of CBT shares?
Over the past week, the price has changed by +2.72%, over one month by +8.37%, over three months by +7.65% and over the past year by -20.57%.
Is Cabot a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CBT is around 83.16 USD . This means that CBT is currently overvalued and has a potential downside of 1.96%.
Is CBT a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85.4 | 4.7% |
| Analysts Target Price | 83.6 | 2.5% |
| ValueRay Target Price | 91.9 | 12.6% |
Last update: 2025-08-18 02:03
CBT Fundamental Data Overview
CCE Cash And Equivalents = 239.0m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 10.2291
P/E Forward = 10.2775
P/S = 1.0899
P/B = 2.6982
P/EG = 1.83
Beta = 0.858
Revenue TTM = 3.81b USD
EBIT TTM = 661.0m USD
EBITDA TTM = 812.0m USD
Long Term Debt = 1.10b USD (from longTermDebt, last quarter)
Short Term Debt = 110.0m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (Calculated: Short Term 110.0m + Long Term 1.10b)
Net Debt = 976.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.13b USD (4.16b + Debt 1.22b - CCE 239.0m)
Interest Coverage Ratio = 8.81 (Ebit TTM 661.0m / Interest Expense TTM 75.0m)
FCF Yield = 6.78% (FCF TTM 348.0m / Enterprise Value 5.13b)
FCF Margin = 9.12% (FCF TTM 348.0m / Revenue TTM 3.81b)
Net Margin = 11.14% (Net Income TTM 425.0m / Revenue TTM 3.81b)
Gross Margin = 25.16% ((Revenue TTM 3.81b - Cost of Revenue TTM 2.85b) / Revenue TTM)
Tobins Q-Ratio = 3.33 (Enterprise Value 5.13b / Book Value Of Equity 1.54b)
Interest Expense / Debt = 1.56% (Interest Expense 19.0m / Debt 1.22b)
Taxrate = 20.98% (from yearly Income Tax Expense: 111.0m / 529.0m)
NOPAT = 522.3m (EBIT 661.0m * (1 - 20.98%))
Current Ratio = 2.13 (Total Current Assets 1.57b / Total Current Liabilities 740.0m)
Debt / Equity = 0.79 (Debt 1.22b / last Quarter total Stockholder Equity 1.54b)
Debt / EBITDA = 1.50 (Net Debt 976.0m / EBITDA 812.0m)
Debt / FCF = 3.49 (Debt 1.22b / FCF TTM 348.0m)
Total Stockholder Equity = 1.44b (last 4 quarters mean)
RoA = 11.08% (Net Income 425.0m, Total Assets 3.84b )
RoE = 29.52% (Net Income TTM 425.0m / Total Stockholder Equity 1.44b)
RoCE = 25.98% (Ebit 661.0m / (Equity 1.44b + L.T.Debt 1.10b))
RoIC = 19.71% (NOPAT 522.3m / Invested Capital 2.65b)
WACC = 7.46% (E(4.16b)/V(5.37b) * Re(9.28%)) + (D(1.22b)/V(5.37b) * Rd(1.56%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.35%
Discount Rate = 9.28% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 70.32% ; FCFE base≈368.4m ; Y1≈304.2m ; Y5≈220.0m
Fair Price DCF = 61.88 (DCF Value 3.29b / Shares Outstanding 53.2m; 5y FCF grow -21.01% → 3.0% )
Revenue Correlation: -61.10 | Revenue CAGR: -6.55%
Rev Growth-of-Growth: -0.23
EPS Correlation: 29.14 | EPS CAGR: 4.69%
EPS Growth-of-Growth: -22.37
Additional Sources for CBT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle